WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
North Korea files shortTennessee Gov. Lee admits defeat in school voucher pushPoland's prime minister celebrates after his party wins a string of cities in mayoral votesHeavy rainstorms kill 4 people in southern China. Ten others are missingChinese museums receive 73 mln visits during Spring Festival holidayFencing mom Arianna Errigo and high jumper Gianmarco Tamberi named Italy's Olympic flagbearers'Classless' fan heckles at wrestler Jordan Burrough at US Olympic trialsSouth Africa's ANC loses another court case against rival party led by former president ZumaAlcaraz and Nadal continue recovery from injuries at Madrid Open while Djokovic skips tournamentSlade Cecconi, Diamondbacks earn 5
2.3394s , 6505.375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Intricacies news portal